Browsing Tag
AbbVie
65 posts
AbbVie wins FDA nod expanding RINVOQ label to Crohn’s disease in major IBD market milestone
Find out how AbbVie’s FDA approval for RINVOQ in Crohn’s disease is reshaping IBD therapy and boosting investor confidence in its post-Humira strategy.
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.
Why OSE Immunotherapeutics stock is moving after Marc Le Bozec replaces Nicolas Poirier as CEO
OSE Immunotherapeutics ousts CEO Nicolas Poirier, names Marc Le Bozec interim chief and launches a strategic review. See what it means for investors.
AbbVie and Calico secure FDA fast track designation for kidney disease therapy ABBV-CLS-628
AbbVie and Calico’s kidney drug ABBV-CLS-628 wins FDA Fast Track status for ADPKD, reshaping biotech strategy and investor sentiment.
AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
AbbVie plans to launch ovarian cancer drug Elahere in UK at U.S. price—testing NICE, NHS, and investor confidence in oncology pricing norms.
AbbVie seeks FDA approval for tavapadon to improve motor control in Parkinson’s disease patients
AbbVie (NYSE: ABBV) files FDA application for tavapadon, a once-daily oral Parkinson’s treatment aiming to improve motor control and expand its neuroscience pipeline.
AbbVie delays Rinvoq generics until 2037—what it means for revenue, risk, and investor confidence
AbbVie secures Rinvoq exclusivity until 2037 through a key settlement, boosting revenue forecasts and pushing back generics—here’s what it means for investors.
Who’s funding the psychedelic revolution in pharma? Follow the money from PIPEs to Big Pharma M&A
Psychedelic biotech is evolving—from VC hype to pharma buyouts. Discover who’s funding the next generation of depression treatments in 2025.
Can short-acting psychedelics solve the scalability problem in depression treatment?
Short-acting psychedelics like bretisilocin could reshape mental health treatment. Can they overcome the clinical bottlenecks faced by psilocybin and ketamine?
AbbVie’s $1.2bn bet on Gilgamesh’s bretisilocin signals a bold push into next-generation antidepressants
AbbVie to acquire Gilgamesh’s bretisilocin for up to $1.2B to expand its psychiatry pipeline. Find out how this short-acting psychedelic could reshape MDD care.